0001104659-24-010101 Sample Contracts
UNDERWRITING AGREEMENT between LIRUM THERAPEUTICS, INC. and THINKEQUITY LLC as Representative of the Several Underwriters LIRUM THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • February 2nd, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations • New York
The undersigned, Lirum Therapeutics, Inc., a corporation formed under the laws of the State of Delaware (collectively with its affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being an affiliate of Lirum Therapeutics, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as set forth below.
Standard Contracts
EMPLOYMENT AGREEMENTEmployment Agreement • February 2nd, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations • New York
This EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of June 17, 2023 (the “Effective Date”) by and between Peter McDonald (“Employee”) and Lirum Therapeutics, Inc., a Delaware corporation (the “Company”). The Employee and the Company are hereinafter referred to individually as a “Party” and together as the “Parties.”
SECOND AMENDMENT TO THE LICENSE AGREEMENTLicense Agreement • February 2nd, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations
This Second Amendment to the License Agreement (this “Second Amendment”) is made and entered into this [11th] day of July 2023, by and among IGF Oncology, LLC, a Delaware limited liability company (“IGF”), and Lirum Therapeutics, Inc., a Delaware corporation (“LIRUM”). IGF and LIRUM are from time to time referred to herein individually as a “Party” or collectively as the “Parties”.
LICENSE AGREEMENTLicense Agreement • February 2nd, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations • New York
This license agreement (this “Agreement”) is entered into as of January 12, 2022 (the “Effective Date”) by and between IGF Oncology, LLC, a Delaware limited liability company, having an address of 7460 Pinehurst Road, Saint Paul, MN 55115 (“IGF”) and Lirum Therapeutics, Inc. a Delaware corporation, having an address of 590 Park Avenue, New York, NY 10065 (“LIRUM”). IGF and LIRUM are from time to time referred to herein individually as a “Party” or collectively as the “Parties”.
THIRD AMENDMENT TO the LICENSE AGREEMENTLicense Agreement • February 2nd, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations
This Third Amendment to the License Agreement (this “Third Amendment”) is made and entered into this 12th day of January 2024, by and among IGF Oncology, LLC, a Delaware limited liability company (“IGF”), and Lirum Therapeutics, Inc., a Delaware corporation (“LIRUM”). IGF and LIRUM are from time to time referred to herein individually as a “Party” or collectively as the “Parties”.
FIRST AMENDMENT TO THE LICENSE AGREEMENTLicense Agreement • February 2nd, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment to the License Agreement (this “First Amendment”) is made and entered into this 11th day of January 2023, by and among IGF Oncology, LLC, a Delaware limited liability company (“IGF”), and Lirum Therapeutics, Inc., a Delaware corporation (“LIRUM”). IGF and LIRUM are from time to time referred to herein individually as a “Party” or collectively as the “Parties”.
